Results 11 to 20 of about 196,164 (338)

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Nature Medicine, 2022
Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue.
Felice Rivellese, Anna Elisa Surace, Katriona Goldmann   +2 more
exaly   +2 more sources

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation [PDF]

Majalah Kedokteran Bandung, 2019
Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131I-Rituximab, has been sucessfully used for treatment of B-Cell NHL.
Martalena Ramli, Basuki Hidayat, Sutari Sutari, Sri Setyowati, Veronica Yulianti Susilo   +4 more
doaj   +2 more sources

Intralesional rituximab injections for orbital granulomatosis with polyangiitis: a case series and literature review

Therapeutic Advances in Ophthalmology
Rituximab, an anti-CD-20 monoclonal antibody, has garnered increasing interest as a therapeutic option in orbital inflammatory disease (OID). We report our institutional experience with intralesional rituximab injections in two cases of orbital ...
Terence Ang, Jessica Y. Tong, Dinesh Selva   +2 more
doaj   +2 more sources

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

Science, 2020
Clustering for the kill Cluster of differentiation 20 (CD20) is a membrane protein that defines most B cell populations and is the target of therapeutic antibodies to treat malignancies and autoimmune disorders. Rougé et al. present the structure of CD20
Lionel Rougé, Micah Steffek, Christine Kugel   +2 more
exaly   +2 more sources

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Journal of Clinical Oncology, 2019
PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia.
Arnon P Kater, John F Seymour, Peter Hillmen   +2 more
exaly   +2 more sources

Case series of low dose rituximab for membranous nephropathy; a single centre experience [PDF]

Journal of Nephropathology, 2023
Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries.
Gerry George Mathew, Jayaprakash Varadharajan, Sreedhar Sailapathy   +2 more
doaj   +1 more source

Management of refractory autoimmune hepatitis with rituximab: a case series. [PDF]

J Med Case Rep
Background and aims Most patients with autoimmune hepatitis respond to the standard of care of prednisolone in combination with a thiopurine, or a second line of mycophenolate mofetil or tacrolimus.
Batt NM, Bloom SD, Haar G, Nicoll AJ.
europepmc   +2 more sources

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Frontiers in Immunology, 2023
BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period.
Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, Pichaya O-Charoen, Prapaporn Pisitkun, Thanitta Suangtamai, Chavachol Setthaudom, Sonphet Chirasuthat, Kumutnart Chanprapaph   +9 more
doaj   +1 more source

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Frontiers in Immunology, 2021
Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving
Maxime Teisseyre, Maxime Teisseyre, Marion Cremoni, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Thomas Crepin, Sylvia Benzaken, Kévin Zorzi, Vincent Esnault, Vesna Brglez, Vesna Brglez, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +15 more
doaj   +1 more source

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

Annals of the Rheumatic Diseases, 2023
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse.
Rona M. Smith, R. Jones, U. Specks, S. Bond, M. Nodale, R. Al-jayyousi, J. Andrews, A. Bruchfeld, B. Camilleri, S. Carette, C. Cheung, V. Derebail, T. Doulton, A. Ferraro, Lindsy J. Forbess, S. Fujimoto, S. Furuta, Ora Gewurz-Singer, L. Harper, T. Ito-Ihara, N. Khalidi, R. Klocke, C. Koening, Y. Komagata, C. Langford, P. Lanyon, R. Luqmani, Carol A. McAlear, L. Moreland, Kim Mynard, P. Nachman, C. Pagnoux, C. Peh, C. Pusey, D. Ranganathan, Rennie L. Rhee, R. Spiera, A. Sreih, Vladamir Tesar, G. Walters, C. Wroe, D. Jayne, P. Merkel   +42 more
semanticscholar   +1 more source